SC
LYEL icon

Steven Cohen’s Lyell Immunopharma LYEL Stock Holding History

Steven Cohen’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$366K Buy
26,080
+4,788
+22% +$86.7K ﹤0.01% 3307
2026
Q1 		$427K Buy
21,292
+9,812
+85% +$229K ﹤0.01% 3188
2025
Q4 		$353K Buy
+11,480
New +$257K ﹤0.01% 3403
2024
Q2 		– Sell
-340
Closed -$15.2K – 2198
2024
Q1 		$15.2K Buy
+340
New +$14.6K ﹤0.01% 2103
2021
Q3 		– Sell
-1,250
Closed -$406K – 1146
2021
Q2 		$406K Buy
+1,250
New +$410K ﹤0.01% 878

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Steven Cohen's LYEL Position: Q2 2026 in Review

Steven Cohen increased its Lyell Immunopharma (LYEL) stake by 22% in Q2 2026, buying an estimated $86.7K and bringing the position to 26,080 shares worth $366K. The position accounts for ﹤0.01% of the portfolio, ranked #3307.

Steven Cohen first reported a position in LYEL in Q2 2021 and has held it in 5 quarters since. The position peaked at $427K in Q1 2026. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • Steven Cohen held 26,080 shares of Lyell Immunopharma worth $366K as of Q2 2026.
  • Steven Cohen bought 4,788 Lyell Immunopharma shares in Q2 2026, an estimated $86.7K.
  • Lyell Immunopharma made up ﹤0.01% of Steven Cohen's portfolio in Q2 2026, its #3307 holding.
  • Steven Cohen first reported a position in Lyell Immunopharma in Q2 2021 and has held it in 5 quarters since.
  • Steven Cohen's Lyell Immunopharma position peaked at $427K in Q1 2026.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.